Clinical Trial Update: Comparison of Two NN1250 Formulations in Healthy Volunteers [Phase 1]

View source ↗

Summary

This Phase 1 trial compares two NN1250 formulations (insulin degludec) in healthy volunteers, sponsored by Novo Nordisk.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• Tresiba (insulin degludec)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Healthy | Phase 1 | Status: COMPLETED